MBX Biosciences, Inc.

About MBX Biosciences, Inc.

MBX Biosciences is a clinical-stage biopharmaceutical company based in Carmel, Indiana and Burlington, Massachusetts, on a mission to transform the lives of people living with obesity and rare endocrine disorders. Leveraging its proprietary peptide delivery platform, MBX is pioneering investigational Precision Endocrine Peptides (PEPs)™ designed to overcome key limitations of existing therapies and enhance efficacy, tolerability, safety and convenience. The Company is advancing a pipeline of novel candidates with clinically validated targets, established endpoints for regulatory approval and strong market potential. The Company’s lead candidate, canvuparatide (MBX 2109) – a potential once-weekly parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism – is preparing for Phase 3 development. The Company’s obesity portfolio includes MBX 4291, a GLP-1/GIP co-agonist prodrug in Phase 1 development, and MBX 5765, an amycretin prodrug in preclinical development. In addition, the Company is on track to nominate its GLP-1/GIP/GCG receptor prodrug candidate in Q3 2026, further expanding its obesity pipeline to potentially address the full spectrum of patient needs. MBX was founded by pioneers in peptide drug development with a strong track record of building companies at the forefront of endocrine and metabolic disease innovation. Learn more about our pipeline and scientific foundation on our website.